Evidence map›Paper›PMID 22536024›Full record

ReviewJournal of biomedicine & biotechnology2012

Classic and new animal models of Parkinson's disease.

Javier Blesa, Sudarshan Phani, Vernice Jackson-Lewis, Serge Przedborski

Registry-linked trialOpen access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of biomedicine & biotechnology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04551040 (Assessing Target Engagement of Terazosin in Healthy Adults), which is not on this map. Cited by 199 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
199citing papers in PubMed, 3 pooled it
32.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04551040 phase1active not recruitingnot on this mapstarted 2021, after this paper: background citation

Assessing Target Engagement of Terazosin in Healthy Adults

TypeinterventionalSponsorUniversity of IowaRan2021 to 2025Enrolled18ConditionsHealthyArmsTerazosin
3 · Its place in the literature

Who cites it

199 citing papers in PubMed, 3 syntheses or guidelines pooled it, 486 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Monoamine Oxidase Inhibitors in Toxic Models of Parkinsonism.International journal of molecular sciences · 2025
    Review
  17. Article
  18. Article
  19. Review
  20. Article

139 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Javier BlesaDepartment of Pathology and Cell Biology, Columbia University, New York, NY 10032, USA.
Sudarshan Phani
Vernice Jackson-Lewis
Serge Przedborski
Columbia University · US

Funding

TRANSLATIONAL APPROACHES TO NEUROPROTECTION OF AXONS IN PDrP50NS038370 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BURKE, ROBERT E · 1999 to 2014
$24.0M
PD iPS Cell Line Research ConsortiumRC2NS070276 · NINDS · MCLEAN HOSPITAL · PI ISACSON, OLE · 2009 to 2010
$3.8M
Proinflammatory enzymes in amytrophic lateral sclerosisR01NS042269 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI PRZEDBORSKI, SERGE E · 2001 to 2012
$3.0M
Pre-clinical testing of necrostatin as a potential small molecule for the treatmeR21NS072182 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI PRZEDBORSKI, SERGE E · 2011 to 2012
$441k
A novel cell-based high-throughput assay for ALSR21NS064191 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI PRZEDBORSKI, SERGE E · 2009 to 2010
$384k
NINDS NIH HHS NS042269NINDS NIH HHS NS064191NINDS NIH HHS NS070276NINDS NIH HHS NS072182NINDS NIH HHS NS38370NINDS NIH HHS P50 NS038370NINDS NIH HHS R01 NS042269NINDS NIH HHS R21 NS064191NINDS NIH HHS R21 NS072182NINDS NIH HHS RC2 NS070276
6 · The paper itself

Abstract

Neurological disorders can be modeled in animals so as to recreate specific pathogenic events and behavioral outcomes. Parkinson's Disease (PD) is the second most common neurodegenerative disease of an aging population, and although there have been several significant findings about the PD disease process, much of this process still remains a mystery. Breakthroughs in the last two decades using animal models have offered insights into the understanding of the PD disease process, its etiology, pathology, and molecular mechanisms. Furthermore, while cellular models have helped to identify specific events, animal models, both toxic and genetic, have replicated almost all of the hallmarks of PD and are useful for testing new neuroprotective or neurorestorative strategies. Moreover, significant advances in the modeling of additional PD features have come to light in both classic and newer models. In this review, we try to provide an updated summary of the main characteristics of these models as well as the strengths and weaknesses of what we believe to be the most popular PD animal models. These models include those produced by 6-hydroxydopamine (6-OHDA), 1-methyl-1,2,3,6-tetrahydropiridine (MPTP), rotenone, and paraquat, as well as several genetic models like those related to alpha-synuclein, PINK1, Parkin and LRRK2 alterations.

Indexed as

Disease Models, AnimalParkinson DiseaseAnimalsHaplorhiniMice

Identifiers

PMID22536024
PMCPMC3321500
OpenAlexW2050865611

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.